News | March 21, 2022
Lonza signs manufacturing agreement with Oasmia Pharmaceutical
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
This pre-packaged release is a ready-to-go solution with powerful, straightforward bioanalysis pipeline support
Machine learning approach to systems biology combined with ligand discovery platform
The facility registration, along with DMF registration and GMP certification provides peace of mind to clients looking to use our iPSCs for clinical and commercial use in the United States, Japan, and other global markets
Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA’ to develop novel mRNA therapeutics that can generate PharmAbcine's antibodies
Its technology-centric solutions enable hospitals to enhance operational efficiency and enable faster clinical decision making
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
Using Orion, pharmaceutical and biotechnology companies, as well as any industrial researcher who wishes to perform electronic structure calculations, can gain access to elastic and flexible computational resources in the Cloud
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
Subscribe To Our Newsletter & Stay Updated
